An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...

Financial toxicity is pervasive in rural oncology, with 53% reporting unaffordable care, 50% carrying medical debt, and 70% ...

NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and ...

An ITT reanalysis assigning 0-month suspension to non-suspenders addressed imbalance in suspension rates (90% combination, 86 ...

Lilit Karapetyan, MD, MS, discusses the importance of considering TIL therapy for melanoma in advance and not as a last ...

The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...

MMRd showed no meaningful association with pOR, pCR, or RFS, suggesting limited utility for selecting patients for Gem-iDRS ...

Two pre-TURBT 40-mg intravesical mitomycin-C instillations significantly improved long-term recurrence outcomes versus TURBT ...

Detalimogene voraplasmid achieved a 54.0% any-time CR in BCG-unresponsive NMIBC with CIS ± high-grade Ta/T1, with 91% of CRs ...

A new program for young cancer patients breaks disease silos, showing how multidisciplinary teamwork improves coordination, ...

CAR T therapy spreads beyond academic centers, but insurance, cost and policy gaps keep most eligible lymphoma patients from ...

Dr. Leal addresses diagnostic challenges with newer therapies, particularly tarlatamab's potential neurologic side effects ...